| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6446627 | TEVA PHARM | Inhaler dose counter |
Dec, 2017
(6 years ago) | |
| US6701917 | TEVA PHARM | Dose counter for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US6748947 | TEVA PHARM | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(2 years ago) | |
| US6871646 | TEVA PHARM | De-agglomerator for breath-actuated dry powder inhaler |
Jun, 2021
(2 years ago) | |
| US6718972 | TEVA PHARM | Dose metering system for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US8006690 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
Jun, 2021
(2 years ago) | |
| US7540282 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(11 months ago) | |
|
US7540282 (Pediatric) | TEVA PHARM | Reservoir pressure system for medicament inhaler |
Nov, 2023
(5 months ago) | |
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(3 months from now) | |
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(9 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 14 days from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 14 days from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(1 year, 6 months from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(1 year, 6 months from now) | |
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(4 years from now) | |
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(7 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(7 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(7 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(7 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(7 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | |
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(7 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(7 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(8 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(8 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(8 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(11 years from now) | |
Armonair Respiclick is owned by Teva Pharm.
Armonair Respiclick contains Fluticasone Propionate.
Armonair Respiclick has a total of 33 drug patents out of which 8 drug patents have expired.
Expired drug patents of Armonair Respiclick are:
- US6446627
- US6701917
- US6748947
- US6871646
- US6718972
- US8006690
- US7540282
- US7540282*PED
Armonair Respiclick was authorised for market use on 08 April, 2022.
Armonair Respiclick is available in powder;inhalation dosage forms.
The generics of Armonair Respiclick are possible to be released after 14 December, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR RESPICLICK family patents
